Oral vaccination with the porcine circovirus type 2 (PCV‐2) capsid protein expressed byLactococcus lactisinduces a specific immune response against PCV‐2 in mice

Authors:

Abstract
Aims PCV2 can cause post‐weaning multi‐systemic wasting syndrome in pigs, which leads to enormous losses in the swine industry worldwide. Here, a genetically engineered Lactococcus strain expressing the main protective antigen of PCV2, the Cap protein, was developed to against PCV2 infection as an oral vaccine. Methods and Results Expression of the Cap protein was confirmed via western blot, ELISA, and fluorescence microscopy. Over 90% of the recombinant pAMJ399‐Cap/MG1363 survived a simulated gastro‐intestinal transit. It also survived the murine intestinal tract for at least 11 days. Then, the safety and immunogenicity of pAMJ399‐Cap/MG1363 in orally immunized mice were evaluated. The levels of the sIgA, IgG, and cytokines (IL‐4 and IFN‐γ) obtained from the mice immunized with pAMJ399‐Cap/MG1363 were significantly higher than those in the control groups. Conclusions pAMJ399‐Cap/MG1363 can survive in the gastro‐intestinal transit and effectively induce mucosal, cellular, and humoral immune response against PCV2 infection via oral administration. Significance and Impact of the study This study demonstrates the potential of the genetically engineered L. lactis as a candidate for an oral vaccine against PCV2.

This publication has 45 references indexed in Scilit: